Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

被引：373

作者：

Schalper, Kurt A. ^{[1
]}

Carleton, Michael ^{[2
]}

Zhou, Ming ^{[3
]}

Chen, Tian ^{[3
]}

Feng, Ye ^{[3
]}

Huang, Shu-Pang ^{[3
]}

Walsh, Alice M. ^{[4
]}

Baxi, Vipul ^{[4
]}

Pandya, Dimple ^{[5
]}

Baradet, Timothy ^{[2
]}

Locke, Darren ^{[2
]}

Wu, Qiuyan ^{[5
]}

Reilly, Timothy P. ^{[5
]}

Phillips, Penny ^{[2
]}

Nagineni, Venkata ^{[1
]}

Gianino, Nicole ^{[1
]}

Gu, Jianlei ^{[6
]}

Zhao, Hongyu ^{[6
]}

Luis Perez-Gracia, Jose ^{[7
,8
]}

Sanmamed, Miguel F. ^{[7
,8
,9
,10
]}

Melero, Ignacio ^{[7
,8
,10
]}

机构：

[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA

[2] Bristol Myers Squibb, Dept Translat Med, Princeton, NJ USA

[3] Bristol Myers Squibb, Dept Global Biometr Sci, Princeton, NJ USA

[4] Bristol Myers Squibb, Dept Translat Bioinformat, Princeton, NJ USA

[5] Bristol Myers Squibb, Dept Res & Early Dev, Princeton, NJ USA

[6] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA

[7] Clin Univ Navarra, Oncol Dept, Pamplona, Spain

[8] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

[9] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA

[10] Univ Navarra, Ctr Invest Med Aplicada CIMA, Dept Immunol & Immunotherapy, Pamplona, Spain

来源：

NATURE MEDICINE | 2020年 / 26卷 / 05期

基金：

欧盟地平线“2020”;

关键词：

SUPPRESSOR-CELLS; NIVOLUMAB; PD-1; IPILIMUMAB; DOCETAXEL;

D O I：

10.1038/s41591-020-0856-x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.

引用

页码：688 / +

页数：16

共 33 条

[21] Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, Nadeem
Havel, Jonathan J.
Makarov, Vladimir
Desrichard, Alexis
Urba, Walter J.
Sims, Jennifer S.
Hodi, F. Stephen
Martin-Algarra, Salvador
Mandal, Rajarsi
Sharfman, William H.
Bhatia, Shailender
Hwu, Wen-Jen
Gajewski, Thomas F.
Slingluff, Craig L., Jr.
Chowell, Diego
Kendall, Sviatoslav M.
Chang, Han
Shah, Rachna
Kuo, Fengshen
Morris, Luc G. T.
Sidhom, John-William
Schneck, Jonathan P.
Horak, Christine E.
Weinhold, Nils
Chan, Timothy A.
[J]. CELL, 2017, 171 (04) : 934 - +
[22] Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
Ribas, Antoni
Martin-Algarra, Salvador
Bhatia, Shailender
Hwu, Wen-Jen
Slingluff, Craig L.
Sharfman, William H.
Hodi, F. Stephen
Urba, Walter J.
Luke, Jason J.
Haanen, John B.
Callahan, Margaret K.
Wolchok, Jedd D.
Chasalow, Scott D.
Ross-Macdonald, Petra
Young, Tina C.
Qureshi, Anila
Horak, Christine E.
[J]. CANCER RESEARCH, 2017, 77
[23] Cancer immunotherapy using checkpoint blockade
Ribas, Antoni
Wolchok, Jedd D.
[J]. SCIENCE, 2018, 359 (6382) : 1350 - +
[24] Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
Sanmamed, M. F.
Perez-Gracia, J. L.
Schalper, K. A.
Fusco, J. P.
Gonzalez, A.
Rodriguez-Ruiz, M. E.
Onate, C.
Perez, G.
Alfaro, C.
Martin-Algarra, S.
Andueza, M. P.
Gurpide, A.
Morgado, M.
Wang, J.
Bacchiocchi, A.
Halaban, R.
Kluger, H.
Chen, L.
Sznol, M.
Melero, I.
[J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1988 - 1995
[25] Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Schalper, Kurt A.
Kaftan, Edward
Herbst, Roy S.
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (09) : 2102 - 2104
[26] Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Schalper, Kurt A.
Brown, Jason
Carvajal-Hausdorf, Daniel
McLaughlin, Joseph
Velcheti, Vamsidhar
Syrigos, Konstantinos N.
Herbst, Roy S.
Rimm, David L.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (03):
[27] Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors
Siemers, Nathan O.
Holloway, James L.
Chang, Han
Chasalow, Scott D.
Ross-MacDonald, Petra B.
Voliva, Charles F.
Szustakowski, Joseph D.
[J]. PLOS ONE, 2017, 12 (07):
[28] Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Templeton, Arnoud J.
McNamara, Mairead G.
Seruga, Bostjan
Vera-Badillo, Francisco E.
Aneja, Priya
Ocana, Alberto
Leibowitz-Amit, Raya
Sonpavde, Guru
Knox, Jennifer J.
Tran, Ben
Tannock, Ian F.
Amir, Eitan
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (06):
[29] Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
[30] Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer
Villarroel-Espindola, Franz
Yu, Xiaoqing
Datar, Ila
Mani, Nikita
Sanmamed, Miguel
Velcheti, Vamsidhar
Syrigos, Konstantinos
Toki, Maria
Zhao, Hongyu
Chen, Lieping
Herbst, Roy S.
Schalper, Kurt A.
[J]. CLINICAL CANCER RESEARCH, 2018, 24 (07) : 1562 - 1573

← 1 2 3 4 →